The Ninth Circuit Court of Appeals ordered the DEA on Monday to respond within 30 days to the suit arguing the agency has been “dragging their heels” for the approval of the medical marijuana company’s API Bulk Manufacturing Registration.
At the Drug Enforcement Agency Drug Diversion Division listening sessions earlier this month, DEA Administrator Anne Milgram said the agency would hold a second comment period on its March NPRM in the months ahead. WHY IT MATTERS The Drug Diversion Division said it was conducting public listening sessions to get input on prescribing controlled substances on telemedicine platforms and to learn about the types of data and its accessibility for use in detecting unlawful drug diversion. The agency invited those interested in presenting to reach out with information about potential safeguards. At the outset, Milgram highlighted the sessions' mission to find a path forward and said, "We will also have another comment period this fall for written comments before any telemedicine regulations are finalized." The sessions were highly curated with Deputy Assistant Administrator Matthew Strait moderating. He said in the "run of show" on day two that the DEA chose 30 presen
The DEA's two days of curated listening sessions showcased ideas for how a special registration eliminating in-person evaluation requirements for medically necessary controlled substances might work, but the agency indicated a need for more specifics.
HARRISBURG — A Pennsylvania lawmaker seeks support for a bill that would criminalize the illicit possession of a powerful animal tranquilizer increasingly attributed to fatal drug overdoses.